GleamWall
中文EN

TWST Twist Bioscience Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1581280 · Fiscal year ends 09/30

Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY22.0%
TTM net income YoY-67.6%
TTM EPS YoY-60.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—

Margins

Gross margin52.4%
Operating margin-30.4%
Net margin-28.3%
FCF margin-19.4%
EBITDA margin-24.7%

Returns

ROE-19.1%
ROA-14.8%
ROIC (approx.)-34.2%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets20.8%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.32x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue10.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q4*2026-09-302026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-31
Income statement
Revenue$126.64M$118.38M$110.72M$103.70M$99.01M$96.06M$92.79M$88.71M
Cost of revenue$59.39M$55.92M$53.59M$49.73M$48.17M$44.76M$46.77M$45.87M
Gross profit$67.25M$62.45M$57.12M$53.97M$50.84M$51.30M$46.03M$42.84M
R&D expense$16.99M$18.02M$19.70M$17.13M$17.01M$18.05M$23.92M$21.31M
SG&A expense$74.68M$80.71M$76.08M$69.74M$63.76M$63.37M$63.67M$56.18M
Operating income-$24.41M-$36.28M-$45.86M-$32.90M-$29.93M-$30.12M-$41.56M-$34.64M
Interest expense——————$143,000$24,000
Pretax income-$20.82M-$34.74M-$43.98M-$30.25M-$26.88M$20.58M-$39.15M-$31.50M
Income tax-$201,000$311,000$43,000$253,000$257,000$191,000$175,000$97,000
Net income-$20.62M-$35.05M-$44.02M-$30.51M-$27.14M$20.39M-$39.33M-$31.59M
EBITDA-$17.32M-$29.78M-$39.76M-$26.71M-$23.93M-$24.32M-$35.46M-$28.26M
EPS (basic)—-0.56-0.71-0.50—0.34-0.66-0.53
EPS (diluted)—-0.56-0.71-0.50—0.33-0.66-0.53
Weighted avg. shares (diluted)—62.40M61.70M61.08M—61.16M59.65M59.16M
Balance sheet
Cash & equivalents$533.99M$117.44M$122.67M$148.59M$183.05M$203.91M$212.95M$224.06M
Short-term investments$47.91M$49.40M$49.00M$49.36M$49.38M$49.42M$46.71M$49.42M
Receivables$70.19M$65.06M$64.15M$50.06M$57.02M$49.85M$49.95M$39.31M
Inventory$46.41M$35.16M$33.52M$32.92M$28.31M$25.94M$20.86M$23.52M
Current assets$737.22M$321.30M$323.44M$303.88M$332.97M$339.78M$338.44M$345.31M
PP&E, net$122.32M$111.89M$111.23M$105.12M$102.28M$95.35M$97.14M$100.67M
Goodwill$82.19M$82.19M$82.19M$82.19M$82.19M$82.19M$85.81M$85.81M
Intangibles$34.16M$12.73M$13.00M$13.16M$13.43M$13.69M$13.95M$14.21M
Total assets$1.12B$672.44M$676.21M$638.09M$641.86M$643.61M$595.62M$608.58M
Current liabilities$125.81M$120.25M$119.98M$80.44M$91.41M$87.07M$74.98M$69.65M
Total liabilities$233.79M$226.70M$221.12M$181.99M$168.90M$165.41M$155.51M$152.64M
Shareholders' equity$888.02M$445.74M$455.09M$456.10M$472.96M$478.20M$440.11M$455.94M
Shares outstanding67.81M62.67M62.15M61.27M60.63M60.17M59.86M59.58M
Cash flow statement
Operating cash flow-$173,000$1.11M-$17.56M-$24.81M-$11.81M-$1.40M-$12.99M-$21.43M
Capital expenditure$19.96M$9.76M$7.89M$9.97M$12.43M$9.16M$4.14M$2.27M
Free cash flow-$20.13M-$8.65M-$25.45M-$34.79M-$24.24M-$10.56M-$17.13M-$23.70M
Investing cash flow-$20.25M-$10.20M-$12.71M-$9.93M-$12.40M-$9.40M-$1.43M-$1.54M
Financing cash flow$438.45M$3.79M$4.14M$298,000$5.57M$1.83M$3.20M$17.94M
Depreciation & amortization$7.10M$6.50M$6.10M$6.19M$6.00M$5.80M$6.10M$6.38M
Stock-based compensation$19.47M$18.18M$18.94M$13.27M$16.08M$16.06M$20.33M$11.99M

Free plan shows the latest 8 periods; Pro shows all 36 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.